19 The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) 20 Mycobacterium tuberculosis prompted the reintroduction of para-aminosalicylic acid 21 (PAS) to protect companion anti-tuberculosis drugs from additional acquired resistance. 22 In sub-Saharan Africa, MDR/XDR tuberculosis with HIV co-infection is common and 23 concurrent treatment of HIV-infection and MDR/XDR t...

Sulphasalazine was developed in the 1930s, initially for use in patients with rheumatic polyarthritis. However, its modest eVects in arthritis were soon overshadowed by the striking benefits seen when the drug was given to patients with active colitis. Controlled clinical trials confirmed the early favourable impressions and established a role for sulphasalazine in the treatment of active disea...

Many laboratories validate DST of the second-line drugs by BACTEC MGIT 960 system. The objective of this study is to evaluate the critical concentration and perform DST for the 2nd line drugs. We evaluated 193 clinical strains of M. tuberculosis isolated from patients in South Korea. Testing the critical concentration of six second-line drugs was performed by MGIT 960 and compared with L-J prop...

BACKGROUND With greater use of immunomodulators in inflammatory bowel disease (IBD), it is uncertain whether concurrent therapy with both 5-aminosalicylic acid [5-ASA, mesalazine (mesalamine)] and an immunomodulator is necessary. AIM To determine whether concurrent therapy with both 5-ASA and immunomodulator(s) improves outcomes in IBD. METHODS Systematic review with search terms 'azathiopr...

Acrylic type polymeric systems having degradable ester bonds linked to the 5-aminosalicylic acid (5-ASA), were synthesized and evaluated for colon targeted drug delivery. The obtained prodrug was characterized by FTIR,HNMR,Melting point and Rf value.In vitro drug release study was conducted at pH 1.2,7.4 and in rat fecal matter. Drug release in rat fecal matter at pH 7.4 was found to be most sa...

Decreased cell mediated cytotoxicity occurs frequently in inflammatory bowel disease, particularly in patients with active disease. It is not clear, however, whether this decrease is caused by the disease or is a consequence of the medical treatment. In this study we evaluated the effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on the in vitro natural killer cell activ...

Para-aminosalicylic acid (PAS), a tuberculostatic agent, was formulated into large porous particles for direct delivery into the lungs via inhalation. These particles possess optimized physical properties for deposition throughout the respiratory tract, a drug loading of 95% by weight and physical stability over 4 weeks at elevated temperatures. Upon insufflation in rats, PAS concentrations wer...

The development of 5-aminosalicylic acid (5-ASA) therapy as a life long treatment for ulcerative colitis is reviewed from its origins in the 1940s to the present day. The drug was designed to treat rheumatoid arthritis, but was found helpful in the management of nine patients with ulcerative colitis. This discovery preceded the emergence of the clinical trial as a tool for assessing a new drug'...

This study was an attempt to determine whether the administration of large doses of para-aminosalicylic acid, 18 to 24 grams a day, was feasible and advantageous in the treatment of pulmonary tuberculosis. Patients for this study were not especially selected. Each one for whom antibacterial therapy was indicated and who had an odd hospital register number, between May 24, 1950 and January 1, 19...

Although it is only two and a half years ago since the first report was published on the antitubercular activity of para-amiiosalicylic acid (PAS), there is already quite a considerable literature on the subject. Much of it is, however, fragmentary and it has appeared in a wide variety of journals, but apart from the early publications of the Swedish workers it has all been written in English. ...